申请人:BioSplice Therapeutics, Inc.
公开号:EP3915367A1
公开(公告)日:2021-12-01
The present invention discloses β-diketones, γ-diketoncs or γ-hydroxyketones or analogs thereof, that activate Wnt/p-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
本发明公开了
β-二酮、γ-二酮或γ-羟基酮或其类似物,它们能激活Wnt/p-catenin
信号转导,从而治疗或预防与
信号转导有关的疾病,如骨质疏松症和骨关节病;成骨不全症、骨缺损、骨折、牙周病、耳硬化症、伤口愈合、颅面缺损、溶瘤性骨病、与中枢神经系统分化和发育有关的脑外伤,包括帕
金森病、中风、缺血性脑病、癫痫、阿尔茨海默病、抑郁症、躁狂症、精神分裂症;眼部疾病,如老年性黄斑变性、糖尿病性黄斑
水肿或视网膜色素变性,以及与干细胞分化和生长有关的疾病,包括脱发、造血相关疾病和组织再生相关疾病。